Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
304 participants
INTERVENTIONAL
2006-04-30
2008-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Assessment of the Effect of Atorvastatin on Prevention of CIN in Patients Undergoing Coronary Angiography
NCT02113540
High Dose Atorvastatin for Preventing Contrast-induced Nephropathy
NCT02114346
Short-term Atorvastatin's Effect on Acute Kidney Injury Following Cardiac Surgery
NCT00791648
Atorvastatin Effect on Contrast Induced Nephropathy in Diabetic Patients Undergoing Elective Coronary Intervention
NCT04375787
Using AtorVASTatin to Prevent VAscular Inflammatory OccLUSion in the Critically Ill
NCT01073800
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Placebo
placebo
Placebo
Atorvastatin
80 mg die of Atorvastatin given at least two days before elective angiography or angioplasty and continued for two days after.
Atorvastatin
80 mg die
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Atorvastatin
80 mg die
Placebo
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* end-stage renal failure requiring dialysis
* refusal to give informed consent
* previous therapy with statin
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Ospedale Misericordia e Dolce
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Mauro Maioli
MD
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Mauro Maioli, MD
Role: PRINCIPAL_INVESTIGATOR
Ospedale Misericordia e Dolce, Prato
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Prato0702
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.